NASDAQ:RNA Avidity Biosciences (RNA) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free RNA Stock Alerts $23.04 -0.51 (-2.17%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$22.78▼$23.9850-Day Range$13.27▼$26.8752-Week Range$4.82▼$27.66Volume1.14 million shsAverage Volume1.18 million shsMarket Capitalization$1.84 billionP/E RatioN/ADividend YieldN/APrice Target$36.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media Get Avidity Biosciences alerts: Email Address Avidity Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside57.7% Upside$36.33 Price TargetShort InterestBearish12.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 4 Articles This WeekInsider TradingSelling Shares$4.69 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.07) to ($3.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.98 out of 5 starsMedical Sector797th out of 918 stocksPharmaceutical Preparations Industry349th out of 402 stocks 3.5 Analyst's Opinion Consensus RatingAvidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvidity Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.52% of the outstanding shares of Avidity Biosciences have been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Avidity Biosciences has recently increased by 15.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNA. Previous Next 2.6 News and Social Media Coverage News SentimentAvidity Biosciences has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Avidity Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 9 people have searched for RNA on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,690,942.00 in company stock.Percentage Held by InsidersOnly 2.00% of the stock of Avidity Biosciences is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($3.07) to ($3.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -7.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -7.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvidity Biosciences has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Avidity Biosciences Stock (NASDAQ:RNA)Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Read More RNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNA Stock News HeadlinesApril 5, 2024 | insidertrades.comArthur A. Levin Sells 20,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockApril 13, 2024 | msn.comUnveiling the key role of RNA modification in HIV-1 survival and replicationApril 18, 2024 | TradeSmith (Ad)A.I. Pioneer Issues Urgent Warning to AmericansWith artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.April 13, 2024 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Rating Reiterated by Needham & Company LLCApril 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)April 4, 2024 | finance.yahoo.comInsider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 SharesMarch 27, 2024 | prnewswire.comAvidity Biosciences to Participate in Upcoming Investor ConferencesMarch 17, 2024 | finance.yahoo.comRNA Apr 2024 17.500 callApril 18, 2024 | TradeSmith (Ad)A.I. Pioneer Issues Urgent Warning to AmericansWith artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.March 16, 2024 | finance.yahoo.comRNA Apr 2024 17.500 putMarch 16, 2024 | finance.yahoo.comRNA Apr 2024 22.500 callMarch 15, 2024 | finance.yahoo.comInsider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA)March 7, 2024 | markets.businessinsider.comAvidity Biosciences: Strong Buy Rating Amidst Positive Clinical Developments and Price Target SurgeMarch 5, 2024 | seekingalpha.comAvidity Biosciences: Targeting A First Ever Approval In DM1 With Improving DataMarch 5, 2024 | markets.businessinsider.comA Closer Look at 5 Analyst Recommendations For Avidity BiosciencesMarch 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Avidity Biosciences Following Promising MARINA-OLE Study Data and RNA AnalysisMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed: Avidity Biosciences’s Promising MARINA-OLE Trial Data Indicates Significant DM1 Treatment BreakthroughMarch 4, 2024 | msn.comAvidity Biosciences Says Lead Program Shows Reversal Of Disease Progression In Neuromuscular DiseaseMarch 4, 2024 | markets.businessinsider.comAvidity Accelerates Phase 3 HARBOR Study Initiation To Q2 - Quick FactsMarch 4, 2024 | finance.yahoo.comAvidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ TrialMarch 4, 2024 | finance.yahoo.comTop 2% Biotech Avidity Collapses Despite 'Positive' Results In Treating Muscular DystrophyMarch 2, 2024 | investing.comAvidity Biosciences secures $400 million in private placementMarch 1, 2024 | finance.yahoo.comAvidity Biosciences Full Year 2023 Earnings: Misses ExpectationsFebruary 29, 2024 | edition.cnn.comAvidity Biosciences IncFebruary 29, 2024 | seekingalpha.comAvidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-WatchFebruary 29, 2024 | prnewswire.comAvidity Biosciences Honors Rare Disease Day®February 29, 2024 | finanznachrichten.deAvidity Biosciences, Inc.: Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent HighlightsSee More Headlines Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/18/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RNA CUSIPN/A CIK1574111 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees253Year FoundedN/APrice Target and Rating Average Stock Price Target$36.33 High Stock Price Target$60.00 Low Stock Price Target$20.00 Potential Upside/Downside+57.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-212,220,000.00 Net Margins-2,219.87% Pretax Margin-2,219.87% Return on Equity-39.74% Return on Assets-34.98% Debt Debt-to-Equity RatioN/A Current Ratio7.58 Quick Ratio7.58 Sales & Book Value Annual Sales$9.56 million Price / Sales192.13 Cash FlowN/A Price / Cash FlowN/A Book Value$6.76 per share Price / Book3.41Miscellaneous Outstanding Shares79,720,000Free Float78,125,000Market Cap$1.84 billion OptionableOptionable Beta0.78 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Troy Edward Wilson J.D. (Age 55)Ph.D., Co-Founder & Chairman Comp: $67.5kMs. Sarah Boyce (Age 52)President, CEO & Director Comp: $1.05MMr. Michael F. MacLean (Age 58)Chief Financial & Chief Business Officer Comp: $701.64kDr. W. Michael Flanagan Ph.D. (Age 62)Chief Scientific & Technical Officer Comp: $678.74kMs. Teresa McCarthy (Age 60)Chief Human Resources Officer Comp: $665.14kMr. Eric B. Mosbrooker (Age 56)Chief Strategy Officer Comp: $42.5kProf. Mark E. DavisScientific Founder, Member of Scientific Advisory Board and Member of Board of ManagersDr. Frank P. McCormick Ph.D. (Age 74)Scientific Founder & Member of Scientific Advisory Board Mr. Geoffrey M. Grande C.F.A.VP of Investor Relation & Corporate CommunicationDr. John W. Wallen III (Age 66)VP of Intellectual Property, General Counsel & Secretary More ExecutivesKey CompetitorsPTC TherapeuticsNASDAQ:PTCTGalapagosNASDAQ:GLPGGeronNASDAQ:GERNAmphastar PharmaceuticalsNASDAQ:AMPHCatalyst PharmaceuticalsNASDAQ:CPRXView All CompetitorsInsiders & InstitutionsMirador Capital Partners LPSold 5,488 shares on 4/18/2024Ownership: 0.059%Hennion & Walsh Asset Management Inc.Bought 1,777 shares on 4/17/2024Ownership: 0.092%Los Angeles Capital Management LLCSold 3,290 shares on 4/5/2024Ownership: 0.071%Arthur A LevinSold 20,000 sharesTotal: $542,200.00 ($27.11/share)Michael F MacleanSold 40,000 sharesTotal: $980,800.00 ($24.52/share)View All Insider TransactionsView All Institutional Transactions RNA Stock Analysis - Frequently Asked Questions Should I buy or sell Avidity Biosciences stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RNA shares. View RNA analyst ratings or view top-rated stocks. What is Avidity Biosciences' stock price target for 2024? 6 brokers have issued 12-month price objectives for Avidity Biosciences' shares. Their RNA share price targets range from $20.00 to $60.00. On average, they expect the company's stock price to reach $36.33 in the next year. This suggests a possible upside of 57.7% from the stock's current price. View analysts price targets for RNA or view top-rated stocks among Wall Street analysts. How have RNA shares performed in 2024? Avidity Biosciences' stock was trading at $9.05 at the beginning of the year. Since then, RNA shares have increased by 154.6% and is now trading at $23.04. View the best growth stocks for 2024 here. When is Avidity Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RNA earnings forecast. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) issued its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.25. The biotechnology company earned $2.19 million during the quarter, compared to analysts' expectations of $32.08 million. Avidity Biosciences had a negative trailing twelve-month return on equity of 39.74% and a negative net margin of 2,219.87%. What ETFs hold Avidity Biosciences' stock? ETFs with the largest weight of Avidity Biosciences (NASDAQ:RNA) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Morningstar US Small Growth (MSGR), Simplify Propel Opportunities ETF (SURI), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO) and Harbor Disruptive Innovation ETF (INNO).iShares Micro-Cap ETF (IWC). What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT). When did Avidity Biosciences IPO? Avidity Biosciences (RNA) raised $150 million in an initial public offering on Friday, June 12th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO. Who are Avidity Biosciences' major shareholders? Avidity Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.09%), Los Angeles Capital Management LLC (0.07%) and Mirador Capital Partners LP (0.06%). Insiders that own company stock include Arthur A Levin, Michael F Maclean, Rtw Investments, Lp, Sarah Boyce and W Michael Flanagan. View institutional ownership trends. How do I buy shares of Avidity Biosciences? Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNA) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.